-
Media ReleaseNovartis confirms unconstrained supply for Pluvicto® and continues to significantly expand the number of treatment centers
-
Media ReleaseNovartis Pluvicto® shows clinically meaningful and highly statistically significant rPFS benefit in patients with PSMA-positive metastatic castration-resistant prostate cancer in the pre-taxane setting
-
Media ReleaseFDA approves Novartis Cosentyx® as first intravenous (IV) formulation interleukin-17A antagonist for rheumatic diseases
-
Media ReleaseNovartis Issues Voluntary Nationwide Recall of One Lot of Sandimmune® Oral Solution (cyclosporine oral solution, USP), 100 mg/mL due to Crystallization
-
Media ReleaseNovartis presents new long-term Leqvio® (inclisiran) data demonstrating consistent efficacy and safety beyond six years
-
Media ReleaseNovartis strengthens commitment to Beacon of Hope initiative, engages new collaborators to support clinical trial diversity, break down economic and education barriers
-
Media ReleaseUS FDA approves expanded indication for Novartis Leqvio® (inclisiran) to include treatment of adults with high LDL-C and who are at increased risk of heart disease
-
Media ReleaseNovartis premieres powerful new docuseries at Tribeca Festival to shine a light on debilitating skin disease
-
Media ReleaseNovartis Scemblix®, with novel mechanism of action, shows superior, long-term efficacy and consistent tolerability in 96-week follow-up of chronic myeloid leukemia trial
-
Media ReleaseNovartis highlights scientific advances with Kisqali, iptacopan, Scemblix and YTB323 data at SABCS and ASH
-
Media ReleaseNovartis expands Beacon of Hope through alliances with Historically Black Medical Schools to address systemic health disparities
-
Media ReleaseNovartis presents pivotal Phase III APPLY-PNH data at ASH demonstrating investigational oral monotherapy iptacopan superiority over anti-C5